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Development of adynamic bone in patients with secondary hyperpara-
thyroidism after intermittent calcitriol therapy. Intermittent caleitriol
therapy is commonly used to treat secondary hyperparathyroidism in
patients undergoing regular dialysis, but there is little available informa-
tion about the histologic response of bone to this form of therapy.
Accordingly, 14 children and adolescents with biopsy-proven secondary
hyperparathyroidism were treated with intermittent oral or intraperitoneal
doses of calcitriol for 12 months. Biochemical indices of mineral metab-
olism including serum intact PTH levelswere measured monthly through-
out the study, and bone biopsies were repeated at the end of treatment,
Before treatment, 11 patients had osteitis fibrosa and three had mild
lesions of secondary hyperparathyroidism. Histologic improvement was
seen in 12 of 14 patients, and osteitis fibrosa resolved in 10 of 11 eases.
Bone formation decreased in all patients during intermittent ealeitriol
therapy, falling from 861 380 to 150 170 m2/mm2/day, P C 0.001.
Bone formation decreased to normal in six patients, but six patients
developed adynamic lesions of bone with subnormal bone formation rates.
Serum PTH and alkaline phosphatase levels declined in those who
developed adynamic bone, but values remained elevated in patients with
normal rates of bone formation at follow-up evaluation. Neither the mean
dose of ealcitriol nor the average dose per kilogram body weight differed
in patients with adynamic lesions. Thus, adynamie renal osteodystrophy
develops in a substantial number of patients during intermittent ealcitriol
therapy. Although declining serum PTH and alkaline phosphatase levels
suggest the development of the adynamie lesion, bone formation de-
creases in some patients despite persistently high serum PTH levels.
Calcitriol may directly suppress osteoblastic activity in patients with
secondary hyperparathyroidism when given in large doses to patients
undergoing peritoneal dialysis.
Intravenous calcitriol is widely used for the control of secondary
hyperparathyroidism in patients undergoing regular hemodialysis
[1—41. Doses are given thrice weekly at the end of each dialysis
session, and serum parathyroid hormone (PTH) levels often
decline during treatment, providing an effective alternative to
conventional therapy with daily doses of oral calcitriol [5]. Intra-
venous caleitriol administration is impractical, however, for those
undergoing long-term peritoneal dialysis, and this currently is the
most common mode of dialysis in children with end-stage renal
disease [6]. Alternative approaches for the management of see-
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ondary hyperparathyroidism in such patients include intermittent
oral or intraperitoneal calcitriol therapy [7, 8].
Several reports suggest that large oral doses of ealcitriol, given
two or three times per week, can lower serum P1'H levels in
patients with secondary hyperparathyroidism, but the histologic
response of bone to this form of therapy has not been described
[7, 8]. Moreover, the relationship between treatment with inter-
mittent doses of caleitriol and the increasing prevalence of
adynamic lesions of renal osteodystrophy in patients undergoing
dialysis remains uncertain [9, 10]. Episodes of hypercaleemia are
common in patients with the adynamic lesion requiring additional
clinical evaluation and adjustments to therapy [11].
Because the skeletal lesions of secondary hyperparathyroidism
often fail to improve in pediatric patients despite treatment with
daily doses of oral calcitriol [12], the current study was undertaken
to characterize the biochemical and histologic responses to inter-
mittent calcitriol therapy in children and adolescents undergoing
peritoneal dialysis.
Methods
Fourteen children and adolescents, aged 13.4 1.1 years,
receiving regular peritoneal dialysis were treated with intermittent
doses of calcitriol thrice weekly for 12 months. Before starting
calcitriol therapy, all patients underwent iliac crest bone biopsy
after double tetracycline labeling, and the skeletal lesions of renal
osteodystrophy were classified as previously described [13].
Eleven patients had overt osteitis fibrosa, and three had mild
lesions of secondary hyperparathyroidism; the duration of dialysis
prior to study did not differ in those with osteitis fibrosa or mild
lesions, and none of the patients had evidence of bone aluminum
deposition by histoehemical staining. Bone biopsy and quantita-
tive histomorphometry of bone were repeated after 12 months of
treatment. All patients had previously been managed with daily
doses of oral calcitriol, but vitamin D therapy was stopped four
weeks before entering the current study; none of the patients had
been treated with intermittent doses of calcitriol prior to entering
the study.
The average duration of dialysis before treatment with caleitriol
was 24.1 8.4 months, and all were managed by continuous
cycling peritoneal dialysis (CCPD). The concentration of calcium
in peritoneal dialysate was 3.5 mEqlliter before and throughout
the study. Eight patients were given calcitriol orally (Rocaltrol',
Hoffman-La Roche, Nutley, New Jersey, USA), whereas six
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patients received calcitriol by direct intraperitoneal instillation of
injectable calcitriol (Calcijex', Abbott Laboratories, Abbott Park,
Illinois, USA) as previously described after the final dialysate
exchange of overnight cycling peritoneal dialysis sessions [14]. The
residual volume of peritoneal dialysate in the abdomen at the end
of nightly dialysis treatments was approximately one-third of the
volume used for each regular dialysate exchange. All doses of
calcitriol were given three times each week in the morning
regardless of the route of administration.
Subjects in the current study were participants in an ongoing
clinical trial designed to compare the efficacy of intraperitoneal
and oral calcitriol for the treatment of secondary hyperparathy-
roidism, and they represent the first 14 subjects to complete one
year of intermittent calcitriol therapy. Because of the small
number of subjects, comparisons between modes of calcitriol
therapy were not done, and the results for the current report
represent combined data for all 14 patients. The primary causes of
renal failure were as follows: focal and segmental glomeruloscle-
rosis in six patients, membranoproliferative glomerulonephritis in
two patients, renal dysplasia in two patients, medullary cystic
disease in one patient and Wilm's tumor in one patient. In two
cases, the primary renal disease was not known.
Calcium carbonate was used as the primary phosphate-binding
agent in all subjects, and doses were adjusted monthly, or more
frequently when indicated, according to the serum levels of
phosphorus. Information on the dietary intake of calcium, phos-
phorus and other nutrients was obtained monthly in all patients
using three-day diet diaries [15]. The initial dose of calcitriol was
1.0 jsg three times per week, and this was adjusted monthly based
upon the results of periodic measurements of serum calcium and
phosphorus concentrations. The dose of calcitriol was raised in
increments of 0.5 jg if serum calcium levels remained below 10.0
mg/dl and serum phosphorus values were less than 6.0 mg/dl.
Calcitriol therapy was discontinued temporarily if serum calcium
levels exceeded 11.5 mg/dl, and treatment was re-started after
reducing the daily dose by 50% following the resolution of
hypercalcemic episodes. Doses of calcitriol were also withheld if
serum phosphorus levels exceeded 7.0 mg/dl. The mean daily dose
of calcitriol for each month of study and the cumulative dose
during the 12 months of follow-up were calculated for each
patient.
Blood samples for subsequent measurements of total calcium,
ionized calcium, phosphorus, alkaline phosphatase, 1,25-dihy-
droxyvitamin D and PTH levels in serum were obtained at the
time of the initial bone biopsy and at monthly intervals thereafter.
All samples for monthly biochemical determinations were ob-
tained 24 hours after regular doses of calcitriol. The study
protocol was approved by the Human Subjects Protection Com-
mittee at UCLA, and written informed consent was obtained from
all patients and their parents.
Histomorphometiy of bone
Quantitative histomorphometry of bone was done as previously
described [13], and the terminology established by the Nomencla-
ture Committee of the American Society for Bone and Mineral
Research was used for the presentation of results [16]. All
histomorphometric data refer to measurements in two dimensions
[16]. Reference values for normal subjects were obtained from
iliac crest bone biopsies done in 29 children between the ages of
2.5 and 17 years who had undergone elective orthopedic or
urologic surgical procedures. None of these subjects had clinical
or biochemical evidence of metabolic bone disease, diabetes or
renal insufficiency. All were physically active according to age [13],
and none had a history of treatment with corticosteroids, anticon-
vulsant medications or vitamin D preparations.
Patients with renal osteodystrophy were classified as previously
described using histomorphometric criteria with reference to
values established in normal children [13]. Histopathologic lesions
were defined as follows: osteitis fibrosa—osteoid area <12%,
evidence of tissue fibrosis and bone formation rate (BFR, tissue
referent) >613 m2/mm2/day; mild lesion of secondary hyperpar-
athyroidism—osteoid area <12%, no tissue fibrosis and BFR
>613 m2/mm2/day; normal bone histology—no fibrosis, osteoid
volume >1.0% but <12% and BFR >97 but <613 Lm2/mm2/day;
adynamic bone—osteoid area <12%, no fibrosis and BFR <97
jm2/mm2/day; osteomalacia—osteoid area >12%, no fibrosis and
BFR <97 jLm2/mm2/day; mixed lesion—osteoid area >12% and
fibrosis present [13].
Biochemical deter,ninations
The serum levels of calcium, phosphorus and alkaline phos-
phatase were measured by automated methods as previously
described [13]. Serum PTH levels were measured using a two-site
immunoradiometric assay for the intact hormone (Allegro PTH,
Nichol's Institute, San Juan Capistrano, California, USA) [17];
the reference range for subjects with normal renal function using
this assay is 1.0 to 6.5 pmollliter, or 10 to 65 pglml. Serum
1,25-dihydroxyvitamin D levels were measured by radioreceptor
assay (Nichol's Institute) [18].
Statistical analysis
All results are presented as means standard error. Statistical
analysis of the data was done using one-way analysis of variance
with contrasts, analysis of variance for repeated measures, the
t-test for either paired or unpaired samples and chi-square
analysis [19]. Repeated measures regression analysis was done
using BMDP-5V software [20].
Results
Bone histology
Before treatment, 11 of 14 patients had overt osteitis fibrosa,
whereas three had mild lesions of secondary hyperparathyroidism.
The histologic findings of excess bone resorption were substan-
tially reduced, however, after 12 months of intermittent calcitriol
therapy. Eroded bone perimeter (E.Pm) fell from 9.0 3.2% to
6.0 4.2%, P < 0.05, and the number of patients with marrow
fibrosis decreased (Table 1). Fibrotic changes in bone were
distinctly absent after treatment in all but one patient with osteitis
fibrosa at initial evaluation (Fig. 1), and the extent of marrow
fibrosis decreased markedly in this subject. Osteitis fibrosa re-
solved completely, therefore, in ten of eleven patients.
Histologic evidence of increased bone formation also dimin-
ished during treatment. Osteoid area and osteoid perimeter each
fell moderately, whereas osteoid seam thickness did not change
(Table 1). In contrast, the extent of mineralizing surface within
cancellous bone decreased during the interval between the first
and second biopsy as judged by the uptake of tetracycline into
bone. Double tetracycline-labeled bone perimeter fell by approx-
imately 86% and single tetracycline-labeled perimeter fell by 67%
1162 Goodman et a!: Adynamic bone after intermittent calcitriol therapy
Table 1. Quantitative bone histology before and after intermittent
calcitriol therapy in 14 pediatric patients with secondary
hyperparathyroidism undergoing regular peritoneal dialysis
OF 11
Normal 6
OF 1
Mild 3
Adynamic 6
Initial
Normal
Histologic variable
Initial
(N = 14)
Final
(N = 14)
P
valuea
range(N = 29)
Bone area [B.Arl % 30.3 1.1 27.9 1.5 NS 14.6—34.4
Osteoid area [O.Ar] % 5.9 0.9 3.7 0.8 NS 0.2—2.4
Osteoid perimeter 38,7 3.6 27.7 4.7 NS 4.3—37.5
lO.Pml %
Osteoid seam thickness 10.9 0.7 9.5 0.7 NS 4.1—13.2
[O.Th] pin
Eroded perimeter [E.Pm] 9.0 0.8 6.0 1.0 <0.05 0.5—4.3
%
Double-labeled perimeter 13.5 1.5 1.9 0.7 <0.001 0.3—15.9
[dLS] %
Single-labeled perimeter 15.9 1.8 5.2 1.4 <0.001 0.4—12.6
[sLS} %
Mineralizing perimeter 21.5 2.1 4.6 1.2 <0.001 2.3—7.6
[dLS + (sLS/2)] %
Mineralizing osteoid 60 7 21 6 <0.001 11.4—83.1
EM.Pm/O.Pml %
Adjusted apposition rate 0.63 0.08 0.25 0.09 <0.01 0.14—0.81
[Aj.AR] pin/day
Trabecular width [Th.Wi] 156 5 168 6 NS 91—220
pin
Trabecular spacing 363 15 454 31 NS 35 1—737
[Th.Sp] pm
Final
Fig. 1. Histologic classification of renal osteodystrophy before and after
treatment with intermittent doses of calcitriol in 14 pediatric patients under-
going peritoneal dialysis.
Values obtained in 29 children and adolescents without renal disease
are provided for reference. Values are means SE.
a Initial vs. final; probabilities determined by paired t-test
(Table 1); the percentage of osteoid seams undergoing active
mineralization also decreased (Table 1).
These changes resulted in a marked reduction in mineralized
bone formation. Adjusted mineral apposition rate declined by
approximately 60% (Table 1), and the rate of bone formation fell
from 861 380 to 150 170 gm2lmm2/day, P < 0.001 (Fig. 2).
Bone formation decreased in all but one patient, including all 11
patients with osteitis fibrosa. At the time of repeat bone biopsy,
none of the patients had a value for bone formation that exceeded
the upper limit of normal (Fig. 2), and none had histochemical
evidence of bone aluminum deposition.
Six of 14 patients developed adynamic lesions of renal osteodys-
trophy during intermittent calcitriol therapy (Fig. 1); these pa-
tients had subnormal rates of bone formation without histologic
evidence of osteomalacia or marrow fibrosis at the time of the
second bone biopsy. For these six subjects, the initial bone biopsy
demonstrated osteitis fibrosa in four and mild lesions of secondary
hyperparathyroidism in two.
Six other patients had normal rates of bone formation on repeat
bone biopsy evaluation, and these were categorized as normal
bone histology (Fig. 1). Of the remaining two patients, one had
persistent peri-trabecular fibrosis on repeat examination, but
eroded bone perimeter fell and the rate of bone formation
decreased to normal, changes indicative of histologic improve-
ment. One patient developed a mixed lesion of renal osteodystro-
phy (Fig. 1). The histologic severity of secondary hyperparathy-
roidism before treatment did not differ between patients with
adynamic lesions or normal rates of bone formation at the end of
study (Table 2).
$ 2000
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Initial Final
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Fig. 2. The rates of bone formation in 14 pediatric patients with secondary
hyperparathyroidism before and after treatment with intermittent calcitriol. ap
<0.05 initial vs. final. The rectangle depicts the range of bone formation
for children and adolescents with normal renal function.
Serum biochemical determinations
Serum calcium levels increased during calcitriol therapy, and
values were greater than pre-treatment levels at each monthly
interval during the study (Fig. 3). Calcium levels did not differ,
however, between patients with and without the adynamic lesion
at follow-up evaluation, although values tended to be higher
during the fifth through the eighth month of treatment in those
with adynamic bone (Fig. 3). Serum ionized calcium levels also
rose during treatment (data not shown), but values were no higher
in patients who developed adynamic lesions. There were nine
episodes of hypercalcemia with calcium levels above 11.5 mg/dl, or
2.88 mmol/liter; four of these occurred in patients with adynamic
lesions, whereas five occurred in subjects with other histologic
findings.
Serum phosphorus levels remained stable during follow-up, and
monthly values did not exceed baseline levels (Fig. 3). Indeed,
serum phosphorus levels decreased during the second, sixth and
eleventh month of study (Fig. 3). Serum phosphorus levels did not
differ between those with and without the adynamic lesion at
follow-up evaluation; dietary phosphorus intake averaged 630
29 mg/day and 749 54 mg/day, respectively, in these two groups
(NS).
Overall, serum PTH levels were markedly elevated before
treatment, but mean values did not change substantially over the
12 months of study when assessed by repeated measures analysis,
P = 0.37 (Fig. 4). Pre-treatment levels were somewhat lower,
however, in patients who developed adynamic lesions, and values
decreased over time particularly during the initial five to six
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Table 2. Pre-treatment bone biopsy findings in patients with either
adynamic lesions or normal bone formation after one year of therapy
with intermittent calcitriol
Normal
Histologic variable
Adynamic(N = 6)
histology(N = 6) P value
Osteoid area [OAr] % 5.8 1.5 7.5 1.8 NS
Osteoid perimeter [O.Pm] % 41.1 5.9 43.5 7.5 NS
Eroded perimeter [E.Pm] % 8.1 1.3 9.8 1.0 NS
Double-labeled perimeter 18.5 2.3 13.7 1.9 NS
[dLS] %
Bone formation rate [BFR/
B.Ar] 1wn2/mm2lday
1061 148 938 142 NS
Time, months
Fig. 4. Serum PTHleveLc during intermittent calcitriol therapy in 14 pediatric
patients with secondaiy hyperparathyroidism. The results for all patients
(N = 14, A) and for patients with (N = 6, •) and without (N = 8, )
adynamic lesions of renal osteodystrophy at follow-up evaluation are
depicted separately. Values are means SE. *D < 0.05 represents the
overall comparison of PTH values during the 12 month study using
repeated measures analysis of variance for patients with and without
adynamic lesions at follow-up evaluation.
Time, months
Fig. 5. Serum alkaline phosphatase levels during intermittent calcitriol ther-
apy in 14 pediatric patients with secondaty hyperparathyroidism. The results
for all patients (N = 14, A) and for patients with (N = 6, •) and without(N = 8, 0) adynamic lesions at follow-up evaluation are depicted
separately. Values are means SE. < 0.05 represents the overall
comparison of alkaline phosphatase values during the 12 month study
using repeated measures analysis of variance for patients with and without
adynamic lesions at follow-up evaluation.
As expected, the serum levels of calcitriol were subnormal
before treatment, but mean values at each monthly interval were
within the normal range (Fig. 6). The average dose of calcitriol
during the study was 1.25 0.29 g, or 0.032 0.008 ig/kg, thrice
weekly. The mean dose of calcitriol did not differ, however,
between patients who developed adynamic bone, 1.26 0.34 xg
(range 0.61 to 2.88 g) or 0.036 0.008 gfkg and those with
other histologic lesions at follow-up examination, 1.25 0.26 g
(range 0.54 to 2.29 p.g) or 0.029 0.008 j.tg/kg, NS. Similarly, the
cumulative dose of calcitriol for the 12 month study was no greater
in patients who developed adynamic bone, 5.71 1.40 .tg/kg, than
in those with other histologic lesions, 3.90 1.02 igfkg, NS.
Discussion
The results of the current study indicate that intermittent
calcitriol therapy markedly lowers the rate of bone formation and
100
80
60
40
20
0 0 1 2 3 4 5 6 7 8 9 10 11 12
B
a,(0
-C0123456789101112 0
Time, months
E
ci)
Cl)
800
600
400
200
0
*
Values are means SE.
Probabilities determined by the t-test for unpaired samples.
A
_ 3.00
2.75
2.50
2.25
2.00
1.75
'° 1.50
3.00
2.50
o 2.00
-C0.
Cl)0
1.50
E
w 1.00 0 1 2 3 4 5 6 7 8 9 10 11 12
Fig. 3. Serum calcium (A) and phosphorus (B) levels during intermittent
calcitriol therapy in 14 pediatric patients with secondaty hypetparathyroidism.
Patients who developed adynamic lesions (•) were compared to those
with other histologic findings (0) on repeat evaluation. Values are means
SE.
months of therapy (Fig. 4). In contrast, serum PTH levels tended
to increase after the first month of study in patients with other
histologic findings on repeat evaluation, P = 0.07 (Fig. 4). Serum
alkaline phosphatase levels also did not change from pre-treat-
ment values when all 14 patients were considered (Fig. 5), but
levels were substantially lower both before and during treatment
in those who developed adynamic lesions (Fig. 5).
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Fig. 6. The serum levels of calcitriol (A) and the average daily dose of
calcitriol (B) during each month of study in 14 pediatric patients treated with
intermittent doses of calcitrioL Normal values for adolescent and young
adult subjects range from 20 to 80 pg/mI. Those who developcd adynamic
lesions (N = 6, •) were compared to patients with other histologic
findings (N = 8, D) on repeat evaluation. Values are means SE.
corrects many of the histologic changes of secondary hyperpara-
thyroidism in children and adolescents undergoing regular pen-
toneal dialysis. Overall, serum PTH levels decreased during the
first six to eight months of therapy, but sustained reductions in
serum PTH levels were not achieved after one year. Because
persistently high serum PTH levels are usually accompanied by
histologic evidence of increased bone resorption and bone forma-
tion, the biopsy results after 12 months of treatment with calcitriol
were unexpected. This disparity between histologic and biochem-
ical findings suggests that intermittent calcitriol administration
can reduce bone formation and turnover in patients with second-
ary hyperparathyroidism, at least in part, by a mechanism that is
independent of vitamin D-induced reductions in the serum levels
of PTH. Calcitriol may, therefore, directly suppress osteoblastic
activity in vivo and contribute to the development of adynamic
bone when given in large doses to patients with end-stage renal
disease.
In the past, the adynamic lesion of renal osteodystrophy
occurred predominantly in dialysis patients with evidence of
substantial aluminum accumulation in bone and other tissues [2,
21]. Additional causes of adynamic bone include diabetes, corti-
costeroid therapy, hyperparathyroidism and idiopathic osteopo-
rosis [2, 21]. These factors are unlikely to account for the
development of the adynamic lesion in pediatric patients treated
with intermittent doses of calcitriol. No histochemical evidence of
bone aluminum deposition was found either before or after
treatment in subjects enrolled in the current study, none of the
patients were diabetic and none had received treatment with
corticosteroids. Moreover, all patients had biopsy-proven second-
ary hyperparathyroidism prior to treatment, and serum PTH
levels remained elevated in some patients despite the continued
administration of calcitriol.
The current results are qualitatively similar to those reported by
Andress et al after treatment with intravenous calcitriol in 10
adult hemodialysis patients with severe osteitis fibrosa who had
failed treatment with daily doses of oral calcitriol [5]. Although
none of their patients developed adynamic lesions, osteoblastic
activity decreased and the rate of bone formation fell in all but
one patient [5]. As in the current study, the reduction in bone
formation was substantially greater than the decrease in bone
resorption as judged by the extent of eroded perimeter within
cancellous bone; such findings are consistent with divergent
effects of calcitriol on the osteoblast and the osteoclast. The
higher incidence of adynamic bone after intermittent cálcitriol
therapy in the current study may be due, at least in part, to the
concurrent use of oral calcium carbonate rather than alumi-
num hydroxide as the primary phosphate-binding agent since
calcium carbonate has been implicated as a predisposing factor
for the development of adynamic bone [10, 22]. Also, all subjects
in the current study were managed by peritoneal dialysis, and the
adynamic lesion has been reported to be more frequent in those
undergoing peritoneal dialysis rather than hemodialysis [9].
A striking result of the current study was the finding that serum
PTH levels remained elevated in some patients during intermit-
tent calcitriol therapy despite marked reductions in bone forma-
tion. Previous reports have shown the immunoradiometric assay
(IRMA) for intact parathyroid hormone to be a reliable non-
invasive tool for evaluating the severity of secondary hyperpara-
thyroidism in adolescents and young adults receiving hemodialysis
and in pediatric patients treated with daily doses of oral calcitriol
during peritoneal dialysis [11, 231. Serum PTH levels are only
moderately elevated in patients with the adynamic lesion, and
values are usually less than 15 pmol/liter, or approximately 150
pg/mi, which is 2 to 2.5 times the upper limit of normal for this
assay [11, 23]. In contrast, serum PTH levels are consistently
above 20 pmol/liter, or 200 pg/mI, in patients with histologic
evidence of overt secondary hyperparathyroidism [11, 23].
In the current study, serum PTH levels declined during treat-
ment in those who developed adynamic bone, and mean values at
the end of study were approximately 15 pmol/liter, or 150 pg/mI.
Thus, the adynamic lesion of renal osteodystrophy may reflect a
state of relative hypoparathyroidism in patients with end-stage
renal disease [10]. Parathyroid hormone-mediated decreases in
bone formation do not fully account, however, for the marked
reduction in bone turnover in patients treated with intermittent
doses of calcitriol. Serum PTH levels remained substantially
elevated in subjects with normal rates of bone formation at
follow-up evaluation, averaging 46 22 pmol/liter, or 460 220
pg/ml, in these six patients during the final three months of study.
Accordingly, intermittent calcitriol therapy markedly altered the
response of bone to persistently high serum levels of PTH; such
findings suggest that calcitriol can directly suppress osteoblastic
activity in vivo in patients who are also taking large doses of oral
calcium supplements. Whether alterations in vitamin D receptor
expression during high-dose, intermittent calcitriol therapy ac-
count for these findings remains to be determined.
Calcitriol, or 1,25-dihydroxyvitamin D, is an important regula-
tor of osteoblastic activity and bone metabolism; 1,25-dihydroxyvi-
tamin D promotes the differentiation of precursor cells into
mature osteoblasts, and it enhances various differentiated osteo-
blastic functions including alkaline phosphatase activity and os-
teocalcin production [24, 25]. Calcitriol has distinct anti-prolifer-
ative actions, however, in several tissues such as parathyroid and
skin [26, 27], and it reduces collagen synthesis by osteoblasts [25,
28, 29]. The current in vivo findings are consistent with the view
that the administration of large doses of calcitriol lowers osteo-
blast proliferation leading to a reduction in the number of sites of
active new bone formation in cancellous bone as judged by
decreases in mineralizing perimeter. The decline in adjusted
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mineral apposition rate also suggests that intermittent calcitriol
therapy reduces the activity of fully differentiated osteobiasts.
Adynamic renal osteodystrophy after treatment with vitamin D
sterols has not previously been described in patients with second-
ary hyperparathyroidism, although marked reductions in serum
PTH levels after parathyroidectomy can lead to subnormal rates
of bone formation and turnover in those undergoing regular
dialysis [30]. Accordingly, over-suppression of parathyroid gland
function during calcitriol therapy may account for the develop-
ment of adynamic lesions in some patients. It is probably desirable
to avoid such an outcome, but there are little available data
regarding the long-term consequences of the adynamic lesion
either in children or in adults. Information about the relative
frequency of the adynamic lesion of renal osteodystrophy after
treatment with either large intermittent doses or smaller daily
doses of calcitriol is not yet available and must await the results of
direct comparative studies.
Based upon the current findings, a serum PTH level below 20
pmollliter, or 200 pg/mi, strongly suggests the development of
adynamic bone during calcitriol therapy. Some patients, however,
experience substantial decreases in bone formation and turnover
despite persistently high serum PTH levels. Thus, only moderate
reductions in the serum levels of PTH during intermittent calcit-
riol therapy do not exclude a favorable skeletal response to this
form of therapy. In this regard, measurements of serum alkaline
phosphatase levels may provide useful additional information
about the evolution of hyperparathyroid bone disease during
intermittent calcitriol therapy.
The time at which blood samples were obtained and its
relationship to the schedule of calcitriol administration are im-
portant considerations which may contribute to the disparity
between the biochemical and histologic findings in the current
study. In the current study, serum samples for PTH determina-
tions were obtained 24 hours after the previous dose of calcitriol,
but it is possible that serum PTH levels were substantially lower
during the interval shortly after calcitriol administration. There is
little information about short-term changes in serum PTH levels
over several hours or days immediately following large doses of
calcitriol, and fluctuations in serum PTH values during the 48 to
72 hours between thrice weekly doses of calcitriol could under-
mine the value of PTH determinations as a non-invasive biochem-
ical index of osteoblastic activity [31]. Additional assessments of
the relationship between the serum levels of PTH and the
dynamics of bone formation during high dose intermittent calcit-
riol therapy will be required to establish the appropriate thera-
peutic target range for this biochemical marker as a non-invasive
index of skeletal turnover in patients with renal osteodystrophy.
The long-term consequences of the adynamic lesion have yet to
be determined, particularly in children. Sustained reductions in
bone formation and turnover may adversely affect longitudinal
bone growth during skeletal development, but there are currently
no published data that specifically address this issue. Whether
certain types of renal osteodystrophy account for the sup-optimal
response to recombinant human growth hormone (rhGH) in
children undergoing regular dialysis is not known [32]. Hypercal-
cemia is a relatively common occurrence, however, in the clinical
management of patients with the adynamic lesion, and adjust-
ments to the dose of calcitrioi, to the amount of oral calcium
supplement prescribed or to the concentration of calcium in
dialysate are often required [11, 33]. Recognition of patients with
this disorder is, therefore, an important clinical issue.
The results of the current investigation indicate that intermit-
tent calcitriol therapy effectively reverses the high rates of bone
formation and turnover that characterize patients with overt
secondary hyperparathyroidism. Although marked reductions in
serum PTH levels during intermittent calcitriol therapy suggest
the development of adynamic renal osteodystrophy, bone forma-
tion may decline despite persistently high serum levels of PTH
and/or alkaline phosphatase. Most published recommendations
about the level of PTH in serum that reflects adequate control of
secondary hyperparathyroidism without suppressing bone forma-
tion and turnover in patients with end-stage renal disease are
based upon studies of untreated patients or those receiving daily
oral calcitriol therapy [11,34, 35]. The current results indicate that
such guidelines may not be suitable for the longitudinal assess-
ment of patients given large intermittent doses of calcitriol.
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